WA treatment (in doses of 25, 50, and 100 mg/kg body weight) significantly reduced the infarct area in a carotid ligation model; WA reduced intimal hyperplasia and proliferating cell nuclear antigen (PCNA)-positive cell counts and suppressed PI3K/Akt signaling following cerebral ischemia/reperfusion injury. The gene discussed is AKT1; the disease is brain ischemia.